Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher disease.
Gaucher disease
LysoGb1
enzyme replacement therapy, ERT
glucocerebrosidase
home therapy
rapid infusion
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
26 Jul 2023
26 Jul 2023
Historique:
received:
15
02
2023
accepted:
18
06
2023
medline:
26
7
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
aheadofprint
Résumé
Enzyme replacement therapy (ERT) has revolutionised the management of patients with Gaucher disease (GD). In 2018, we published the safety and efficacy of rapid 10-min infusion of velaglucerase alfa in previously treated patients, mostly on low-dose therapy. To improve quality of life (QoL) for patients needing lifelong bi-weekly infusions by introducing a 10-min infusion instead of 1 h per label in patients naive to ERT and on high-dose therapy. Fifteen naive patients were enrolled; all received bi-weekly infusions of 60 units/kgBW velaglucerase alfa; the infusion rate was gradually reduced in the hospital, followed by home infusions. Each infusion was followed for safety. Efficacy parameters were assessed every 3 months. Patient-reported outcome questionnaires were collected at baseline and follow-up. Ten-minute rapid infusions were well tolerated without related severe adverse events (SAEs). Two patients experienced a non-related SAE and another a possibly related AE. In three patients, the infusion rate was increased to 30 or 60 min (two because of suboptimal response and one because of AE). Two patients dropped out because of an unwillingness to attend follow-up visits during the COVID-19 pandemic. All 13 remaining patients reached the 24-month end-point. The platelet counts increased by a median (range) of 68.38% (12.5-300%) and the lyso-Gb1 levels decreased by 62.6% (32.9-89.9%). Home therapy with rapid infusion of high-dose velaglucerase alfa was a safe, effective and preferable alternative for patients with GD naïve to treatment. We believe that shortening the infusion time improves the QoL of patients with GD who have a lifelong commitment to intravenous therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Enzyme replacement therapy (ERT) has revolutionised the management of patients with Gaucher disease (GD). In 2018, we published the safety and efficacy of rapid 10-min infusion of velaglucerase alfa in previously treated patients, mostly on low-dose therapy.
AIM
OBJECTIVE
To improve quality of life (QoL) for patients needing lifelong bi-weekly infusions by introducing a 10-min infusion instead of 1 h per label in patients naive to ERT and on high-dose therapy.
METHODS
METHODS
Fifteen naive patients were enrolled; all received bi-weekly infusions of 60 units/kgBW velaglucerase alfa; the infusion rate was gradually reduced in the hospital, followed by home infusions. Each infusion was followed for safety. Efficacy parameters were assessed every 3 months. Patient-reported outcome questionnaires were collected at baseline and follow-up.
RESULTS
RESULTS
Ten-minute rapid infusions were well tolerated without related severe adverse events (SAEs). Two patients experienced a non-related SAE and another a possibly related AE. In three patients, the infusion rate was increased to 30 or 60 min (two because of suboptimal response and one because of AE). Two patients dropped out because of an unwillingness to attend follow-up visits during the COVID-19 pandemic. All 13 remaining patients reached the 24-month end-point. The platelet counts increased by a median (range) of 68.38% (12.5-300%) and the lyso-Gb1 levels decreased by 62.6% (32.9-89.9%).
CONCLUSION
CONCLUSIONS
Home therapy with rapid infusion of high-dose velaglucerase alfa was a safe, effective and preferable alternative for patients with GD naïve to treatment. We believe that shortening the infusion time improves the QoL of patients with GD who have a lifelong commitment to intravenous therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Takeda Pharmaceutical Company
Informations de copyright
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Revel-Vilk S, Szer J, Zimran A. Chapter 72: Gaucher disease and related lysosomal storage diseases. In: Williams Hematology, 10th edn; McGraw Hill, NY. 2021.
Elstein D, Abrahamov A, Oz A, Arbel N, Baris H, Zimran A. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease. Blood Cells Mol Dis 2015; 55: 415-418.
Revel-Vilk S, Szer J, Mehta A, Zimran A. How we manage Gaucher disease in the era of choices. Br J Haematol 2018; 182: 467-480.
Zimran A, Revel-Vilk S, Becker-Cohen M, Chicco G, Arbel N, Rolfs A et al. Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease. Am J Hematol 2018; 93: E246-E248.
Becker-Cohen M, Szer J, Arbel N, Frydman D, Dinur T, Istaiti M et al. Rapid velaglucerase alfa infusion for Gaucher disease: 5-year data. Intern Med J 2022; 52: 1645-1646.
Zimran A, Elstein D, Kannai R, Zevin S, Hadas-Halpern I, Levy-Lahad E et al. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med 1994; 97: 3-13.
Revel-Vilk S, Fuller M, Zimran A. Value of Glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review. Int J Mol Sci 2020; 21: 7159.
Dinur T, Istaiti M, Frydman D, Becker-Cohen M, Szer J, Zimran A et al. Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease. Orphanet J Rare Dis 2020; 15: 284.
Cohn Adulamy M, Shalev V. COLONSCORE: the use of machine learning of big data to detect colorectal cancer. Harefuah 2018; 157: 634-637.
Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010; 116: 893-899.
Margas W, Wojciechowski P, Toumi M. Impact of the COVID-19 pandemic on the conduct of clinical trials: a quantitative analysis. J Mark Access Health Policy 2022; 10: 2106627.
Pastores M, Weinreb N, Aerts H, Andria G, Cox T, Giralt M et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41: 4-14.